Newer anti-VEGF drugs, brolucizumab and faricimab, have recently been approved for the treatment of neovascular age-related macular degeneration, and faricimab is also approved for use in diabetic macular edema (28, 29). This evidence concerns the gene VEGFA and wet macular degeneration.